Metastatic Renal Cancer Clinical Trial
Official title:
A Pilot Study Evaluating the Tolerability of a Ketogenic Diet With Vitamin Supplementation for Patients Receiving First Line Treatment for Metastatic Renal Cell Carcinoma
The purpose of this study is to evaluate the tolerance of one year of ketogenic diet associated with vitamin supplementation in patients treated for a metastatic renal cell carcinoma.
This research study is a pilot study evaluating the tolerance of a ketogenic diet associated
with a standard of care in patient with metastatic renal cell carcinoma.
The drugs involved in this study could be NIVOLUMAB + IPILIMUMAB, PEMBROLIZUMAB + AXITINIB,
SUNITINIB or PAZOPANIB.
Cancer cells are known to have an increased glycolytic activity that allows them to product
energy from anaerobic degradation of glucose. A ketogenic diet places the body in ketosis
state. It forces the body to burn fat instead of glucose. Fat metabolism occurs via the
mitochondrial oxidative phosphorylation. By reducing sugar intake and regulating energy
metabolism, the ketogenic diet could contribute to limit tumor progression.
This diet will be introduced during one year, patient will be monitored closely with
biological tests and radiological assessments every three month.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02479490 -
PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI
|
Phase 2 | |
| Terminated |
NCT01457131 -
Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer
|
Phase 1 | |
| Terminated |
NCT02837757 -
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
|
N/A | |
| Recruiting |
NCT05796973 -
Measuring Oncological Value of Exercise and Statin
|
Phase 3 | |
| Recruiting |
NCT03630692 -
Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs
|
||
| Terminated |
NCT01160445 -
Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer
|
Phase 2 | |
| Terminated |
NCT01273181 -
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
|
Phase 1/Phase 2 | |
| Completed |
NCT02086734 -
Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma
|